HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Necrostatin-1 alleviates reperfusion injury following acute myocardial infarction in pigs.

AbstractBACKGROUND:
In rodents, it has previously been shown that necrostatin-1 (Nec-1) inhibits RIP1, a central regulator of programmed necrosis, thereby decreasing cell death and reducing infarct size (IS) after ischaemia/reperfusion (I/R) injury. To address unanswered questions on feasibility and efficacy of Nec-1 in a large animal model, we assessed the effects of Nec-1 in a porcine I/R model, relevant to human disease.
MATERIALS AND METHODS:
In Dalland landrace pigs (69 ± 3 kg), I/R injury was induced by a 75-min surgical ligation of the left circumflex coronary artery (LCx). Ten minutes prior to reperfusion, pigs were randomly allocated to different Nec-1 doses (1.0 mg/kg or 3.3 mg/kg) or vehicle treatment (control, CTRL). Functional endpoints and immunohistological analyses were performed 24 h after reperfusion.
RESULTS:
Nec-1 3.3 mg/kg significantly reduced IS (n = 6; 24.4 ± 15.6%) compared to Nec-1 1.0 mg/kg (n = 5; 54.8 ± 16.9%) or CTRLs (n = 6; 62.1 ± 26.6%; P = 0.016). In line, LV ejection fraction (LVEF) was significantly higher in Nec-1 3.3 mg/kg, copared to Nec-1 1.0 mg/kg or CTRL treated animals (50.0 ± 12.0% vs. 32.5 ± 12.9% vs. 31.9 ± 6.6%, respectively, P = 0.015). Hemodynamically, a preserved contractility was observed [end-systolic volume at 100 mmHg (ESV100 )] at 24-h follow-up (87.6 ± 17.3 mL vs. 74.5 ± 41.1 mL vs. 56.8 ± 11.8 mL, respectively, P = 0.032), reflecting improved cardiac function.
CONCLUSIONS:
In the pig model of I/R injury, intravenous administration of Nec-1 prior to reperfusion was an effective and above all practical therapeutic strategy that significantly reduced IS and preserved left ventricular function. These data highlight the potential of cardioprotection as a promising adjuvant therapy in the setting of early reperfusion following I/R injury.
AuthorsStefan Koudstaal, Martinus I F J Oerlemans, Tycho I G Van der Spoel, Aafke W F Janssen, Imo E Hoefer, Pieter A Doevendans, Joost P G Sluijter, Steven A J Chamuleau
JournalEuropean journal of clinical investigation (Eur J Clin Invest) Vol. 45 Issue 2 Pg. 150-9 (Feb 2015) ISSN: 1365-2362 [Electronic] England
PMID25496079 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2014 Stichting European Society for Clinical Investigation Journal Foundation.
Chemical References
  • Cardiotonic Agents
  • Imidazoles
  • Indoles
  • necrostatin-1
Topics
  • Animals
  • Cardiotonic Agents (administration & dosage, pharmacology)
  • Coronary Vessels
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Echocardiography
  • Female
  • Hemodynamics (drug effects)
  • Imidazoles (administration & dosage, pharmacology)
  • Indoles (administration & dosage, pharmacology)
  • Infusions, Intravenous
  • Ligation
  • Myocardial Infarction (physiopathology)
  • Myocardial Reperfusion Injury (physiopathology, prevention & control)
  • Neutrophils (drug effects)
  • Oxidative Stress (drug effects)
  • Random Allocation
  • Sus scrofa
  • Swine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: